Start-Up Previews (02/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Antibody Platforms," features profiles of arGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology. Plus these Start-Ups Across Health Care: BioMarker Strategies, BMEYE, Clear Catheter Systesm, Epicardial Technologies and Optibrium.
You may also be interested in...
Nexfin from BMEYE BV is a noninvasive cardiovascular monitoring system that not only checks blood pressure--heartbeat to heartbeat--but also provides physicians with cardiac output and full hemodynamics data, measured with a finger cuff connected to a wrist unit, which is linked to a monitor.
Epicardial Technologies Inc. is developing a technology platform designed to enable physicians to more easily perform percutaneous, catheter-based ablation of common heart rhythm abnormalities, from the inside or the outside surface of the heart, while protecting the structures surrounding the heart from serious damage or injury. The company says its products will enable electrophysiologists to do what only surgeons can currently accomplish-effectively ablate aberrant electrical signals on the heart's outside surface-without opening the chest.
The days when drug makers could easily sign deals with front-running antibody developers are over, ended by acquisitions and exclusive arrangements for the most desirable targets. arGEN-X BV believes this is but one dynamic that will attract partners to its therapeutic antibody platform, which entails active immunization of llamas. To flaunt the diversity and potency of its "camelid" antibodies, ArGEN-X aims to raise antibodies to traditionally tough targets, such as membrane-bound proteins like GPCRs.